Contineum Therapeutics Inc (CTNM)

$10.98 -0.14 (-1.26%)
Market Cap 306.13M
Revenue (ttm) 0.00
Net Income (ttm) -42.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 86,500
Avg Vol 134,242
Day's Range N/A - N/A
Shares Out 29.18M
Stochastic %K 52%
Beta 1.25
Analysts Strong Sell
Price Target $22.00

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-30...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 333 5280
Address:
3565 General Atomics Court, Suite 200, San Diego, United States
AtomicAIerts
AtomicAIerts Dec. 5 at 11:37 AM
$CTNM AtomicAlerts Scalp Alert Direction: SHORT Entry: $10.99 TP1: $10.29 | TP2: $9.59 | TP3: $8.89 Stop Loss: $11.59 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 4 at 7:49 AM
1ightning® Premium Options Alert (Actionable) Ticker: $CTNM Contract: Dec 19 $17.5C Entry: 2.60 Exit: 4.58 Return: +76.09% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 2:16 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $CTNM **Contract:** Dec 19 $12.5C **Entry:** 0.94 **Exit:** 1.69 **Return:** **+80.73% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Iightning
Iightning Nov. 26 at 5:12 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $0.94 Exit: $1.48 | Profit: 58.13% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 3:20 PM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $0.94 Exit: $1.48 | Profit: 58.13% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:15 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $0.94 Exit: $1.48 | Profit: 58.13% ROI | https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 2:57 PM
Baird has updated their rating for Contineum Therapeutics ( $CTNM ) to Outperform with a price target of 14.
0 · Reply
Iightning
Iightning Nov. 22 at 1:26 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $2.35 Exit: $2.95 | Profit: 25.59% ROI | https://1ightning.com
0 · Reply
rispi
rispi Nov. 21 at 4:20 PM
$CTNM no such a big red for a failure guessing why?
0 · Reply
JarvisFlow
JarvisFlow Nov. 21 at 3:00 PM
RBC Capital has adjusted their stance on Contineum Therapeutics ( $CTNM ), setting the rating to Outperform with a target price of 25 → 22.
0 · Reply
Latest News on CTNM
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 10 days ago

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Nov 21, 2025, 11:49 AM EST - 13 days ago

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Nov 20, 2025, 4:05 PM EST - 14 days ago

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Oct 30, 2025, 4:05 PM EDT - 5 weeks ago

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Sep 18, 2025, 8:05 AM EDT - 2 months ago

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Present at September Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 3 months ago

Contineum Therapeutics to Present at September Investor Conferences

Contineum (CTNM) Q2 R&D Jumps 78%

Aug 5, 2025, 11:34 PM EDT - 4 months ago

Contineum (CTNM) Q2 R&D Jumps 78%

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

Aug 5, 2025, 4:05 PM EDT - 4 months ago

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Jun 25, 2025, 8:15 AM EDT - 5 months ago

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025, 4:05 PM EDT - 7 months ago

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

May 14, 2025, 4:05 PM EDT - 7 months ago

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Apr 28, 2025, 4:05 PM EDT - 7 months ago

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Mar 17, 2025, 4:05 PM EDT - 9 months ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Mar 12, 2025, 4:05 PM EDT - 9 months ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Mar 6, 2025, 4:05 PM EST - 9 months ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Mar 4, 2025, 4:05 PM EST - 9 months ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 9 months ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Jan 8, 2025, 4:05 PM EST - 11 months ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Dec 16, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Nov 18, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Contineum Therapeutics to Attend Upcoming Investor Conferences

Nov 13, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

RNA

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 13, 2024, 2:03 PM EDT - 1 year ago

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

May 20, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 16, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

Apr 6, 2024, 5:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

JNJ LOAR MAMO PACS RBRK ULS ZBAO

Contineum Therapeutics Announces Pricing of Initial Public Offering

Apr 4, 2024, 9:02 PM EDT - 1 year ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

AtomicAIerts
AtomicAIerts Dec. 5 at 11:37 AM
$CTNM AtomicAlerts Scalp Alert Direction: SHORT Entry: $10.99 TP1: $10.29 | TP2: $9.59 | TP3: $8.89 Stop Loss: $11.59 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 4 at 7:49 AM
1ightning® Premium Options Alert (Actionable) Ticker: $CTNM Contract: Dec 19 $17.5C Entry: 2.60 Exit: 4.58 Return: +76.09% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 2:16 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $CTNM **Contract:** Dec 19 $12.5C **Entry:** 0.94 **Exit:** 1.69 **Return:** **+80.73% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Iightning
Iightning Nov. 26 at 5:12 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $0.94 Exit: $1.48 | Profit: 58.13% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 3:20 PM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $0.94 Exit: $1.48 | Profit: 58.13% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:15 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $0.94 Exit: $1.48 | Profit: 58.13% ROI | https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 2:57 PM
Baird has updated their rating for Contineum Therapeutics ( $CTNM ) to Outperform with a price target of 14.
0 · Reply
Iightning
Iightning Nov. 22 at 1:26 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $2.35 Exit: $2.95 | Profit: 25.59% ROI | https://1ightning.com
0 · Reply
rispi
rispi Nov. 21 at 4:20 PM
$CTNM no such a big red for a failure guessing why?
0 · Reply
JarvisFlow
JarvisFlow Nov. 21 at 3:00 PM
RBC Capital has adjusted their stance on Contineum Therapeutics ( $CTNM ), setting the rating to Outperform with a target price of 25 → 22.
0 · Reply
Diplo
Diplo Nov. 21 at 1:46 PM
$CTNM 3k volume so far what a joke
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 21 at 1:25 PM
$CTNM (-8.0% pre) Contineum (NASDAQ: CTNM) Phase 2 PIPE-307 RRMS Trial Misses Endpoints, Shows Safety https://ooc.bz/l/85413
0 · Reply
Iightning
Iightning Nov. 21 at 4:48 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTNM Dec 19 $12 Call | Enter: $2.35 Exit: $2.95 | Profit: 25.59% ROI | https://1ightning.com
0 · Reply
elmono
elmono Nov. 21 at 12:20 AM
$CTNM I see minus 30-50% tomorrow…lets see 🤷‍♂️😏💩
0 · Reply
Diplo
Diplo Nov. 20 at 10:33 PM
$CTNM well i fat fingered a short here. 80k short and im holding. lead candidate missed on both endpoints this will fall.
1 · Reply
aletz
aletz Nov. 20 at 9:58 PM
$CTNM 1. Very low avg. volume almost no retail interest, volume rarely exceeds 100k/day 2. Big tutes or MM manipulating to earn time to exit, you can see the volume went up almost x10 with very little price movement Would be interesting to see what happens tomorrow
0 · Reply
Diplo
Diplo Nov. 20 at 9:52 PM
$CTNM well this short is backfiring so far
1 · Reply
Diplo
Diplo Nov. 20 at 9:43 PM
$CTNM someone big on the bid. i dont buy it
0 · Reply
cubie
cubie Nov. 20 at 9:35 PM
$CTNM first thing u look up for spec bios is always know how much cash they have cubie teaches,
2 · Reply
Diplo
Diplo Nov. 20 at 9:34 PM
$CTNM wheres the volume
1 · Reply
stevenryl86
stevenryl86 Nov. 20 at 9:33 PM
$CTNM no 3!! I thought I going to buy in on huge dip
0 · Reply
TA_Kongen
TA_Kongen Nov. 20 at 9:33 PM
$CTNM Why is this not down 80%? lmao.
0 · Reply